In some preclinical tumor models, blocking of Tim3, along with other checkpoint inhibitors, enhances the antitumor immune response, which can inhibit tumor growth.19 This result suggests that Tim3 may be a potential therapeutic target for MN. The gene discussed is HAVCR2; the disease is neoplasm.